In a study conducted on 153 GBM patients receiving concurrent radiotherapy and temozolomide treatment, it was reported that median overall survival was significantly reduced with a CRP/Albumin ratio of >0.75 compared to a CRP/Albumin ratio of <0.75 (8). This evidence concerns the gene CRP and glioblastoma.